Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+0.9% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

6(85.7%)

Phase 1

1(14.3%)

7Total

N/A(6)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05789355Not ApplicableCompleted

Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)

Role: lead

NCT05791591Not ApplicableCompleted

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Role: lead

NCT05175768Not ApplicableTerminated

Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection

Role: collaborator

NCT06133478Phase 1Completed

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Role: collaborator

NCT04664361Not ApplicableCompleted

Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity

Role: collaborator

NCT04910061Not ApplicableCompleted

Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.

Role: collaborator

NCT04862338Not ApplicableCompleted

Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults

Role: collaborator

NCT04685096Completed

Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo

Role: collaborator

All 8 trials loaded